Baird Upgrades Abbott Laboratories to Outperform with $121 Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: seekingalpha
Abbott Laboratories (ABT) shares rose 3.30% today, reaching a 20-day high, despite the broader market decline with the Nasdaq-100 down 1.62% and S&P 500 down 0.27%.
Baird initiated coverage on Abbott with an Outperform rating and a price target of $121, citing expectations of stable growth driven by upcoming catalysts. Analyst David Rescott forecasts revenue and earnings growth of 6%-8% in the coming years, particularly as Abbott overcomes recent challenges in respiratory and China diagnostics. The $21 billion acquisition of Exact Sciences is expected to dilute earnings initially, but Rescott believes it will lead to double-digit growth by 2027, enhancing investor confidence.
This upgrade comes at a time when Abbott is positioned to outperform its large-cap MedTech peers, potentially attracting increased investor interest in the sector, especially following a significant decline in its stock price earlier this year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 95.630
Low
136.00
Averages
148.11
High
169.00
Current: 95.630
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Long-Term Investment Strategy in Healthcare Sector
- Strong Financial Performance: Johnson & Johnson reported Q1 revenue of $24.1 billion, a 9.9% increase year-over-year, with adjusted EPS of $2.70 exceeding analyst expectations, and it forecasts annual sales between $99.7 billion and $100.7 billion, indicating robust growth potential in innovative medicine and medtech.
- Diversification Advantage: Abbott Laboratories achieved Q1 sales of $11.2 billion, up 7.8% year-over-year, with strong performance in medical devices and diagnostics offsetting declines in nutrition, and it expects full-year revenue growth of 6.5% to 7.5%, solidifying its position in global healthcare demand.
- Market Dominance: UnitedHealth Group's Q1 revenue reached $111.7 billion, a 2% increase year-over-year, with its Optum division leveraging data analytics and pharmacy care for vertical integration, projecting full-year EPS exceeding $17.35, up at least 31%, reinforcing its leadership in the U.S. private health insurance market.
- Stable Dividend Returns: Johnson & Johnson, Abbott, and UnitedHealth Group are all Dividend Kings, having increased dividends for 64, 54, and 17 consecutive years respectively, showcasing their strong cash flow management and appeal to long-term investors, particularly in times of economic uncertainty, providing low volatility and high margin of safety.
See More
Omnipod 5 Insulin Delivery System Launches in Spain
- Global Expansion: Insulet Corporation has launched the Omnipod 5 Automated Insulin Delivery System in Spain, marking the 26th country for sales and accelerating the company's international growth in diabetes management, which is expected to significantly enhance market share.
- Market Demand: With over 4.6 million adults living with diabetes in Spain, including approximately 189,000 individuals (and over 18,500 children and adolescents aged 0-19) relying on insulin for type 1 diabetes, the introduction of Omnipod 5 will provide these patients with more convenient management tools, improving their quality of life.
- Technological Innovation: The Omnipod 5 system automatically adjusts insulin every five minutes to improve glycemic control and reduce HbA1c levels without the need for multiple daily injections, which is expected to greatly enhance patient adherence and satisfaction with their treatment.
- Data Platform: The newly launched Omnipod Discover data management platform offers clear diabetes data analytics for users and healthcare providers, supporting personalized care and is anticipated to strengthen interactions between patients and their healthcare teams, improving treatment outcomes.
See More
AbbVie Q1 Earnings Beat Expectations, Market Reacts Positively
- AbbVie Revenue Growth: AbbVie reported Q1 revenues of $15 billion, reflecting a year-on-year increase of 12.4% and exceeding analyst expectations by 1.7%, showcasing strong performance from key growth drivers and enhancing the full-year outlook.
- Moderna's Stellar Performance: Moderna achieved Q1 revenues of $389 million, soaring 260% year-on-year and surpassing analyst expectations by 55.8%, marking it as the fastest-growing company among peers, with its stock rising 75.2% since the report, indicating market optimism about its future.
- United Therapeutics Disappoints: United Therapeutics reported revenues of $781.5 million, down 1.6% year-on-year and falling short of analyst expectations, leading to a 3% decline in stock price, highlighting challenges faced in a competitive market.
- Halozyme Exceeds Expectations: Halozyme Therapeutics reported Q1 revenues of $376.7 million, up 42.2% year-on-year and beating analyst expectations by 6.1%, despite a slight miss on full-year EPS guidance, with stock up 16.5%, reflecting market recognition of its technology.
See More
Schwab U.S. Dividend ETF Shows Strong Performance
- CAGR Performance: The Schwab U.S. Dividend ETF has achieved a compound annual growth rate (CAGR) of 13.3% since its inception in 2011, indicating strong performance despite not being available for a full 15 years.
- Dividend Contribution: Approximately 38% of the ETF's total returns come from dividends, highlighting their significance in investment returns; without dividends, an initial $10,000 investment would only be worth about $38,000 today.
- Portfolio Diversity: The ETF currently holds 103 stocks, primarily investing in financially sound U.S. companies that consistently pay dividends, such as Merck, Home Depot, and Coca-Cola, ensuring stability and profitability in its investments.
- Market Comparison: While the Schwab ETF has performed well, an investment of $10,000 in the S&P 500 index fund on October 20, 2011, would have grown to approximately $79,700, illustrating the competitive nature of the market.
See More
The Potential and Returns of Dividend Investing
- Significant Investment Returns: An investment of $10,000 in the Schwab U.S. Dividend Equity ETF 15 years ago would be worth approximately $61,200 today, showcasing the fund's strong performance and appeal.
- Compound Annual Growth Rate: The ETF has achieved a compound annual growth rate of 13.3% since its inception, with an impressive 29% growth rate over the past 12 months, indicating its competitive edge and investment value in the market.
- Importance of Dividends: Dividends accounted for about 38% of total returns since 2011; without them, a $10,000 investment would only be worth $38,000, highlighting the critical role dividends play in investment returns.
- Comparison with S&P 500: While the Schwab ETF has performed well, it still lags behind the Vanguard 500 Index Fund, which would have turned a $10,000 investment into approximately $79,700 during the same period, illustrating the diversity of market options and the importance of selection.
See More
Investment Comparison: Abbott vs. Intuitive Surgical
- Abbott's Diversification Advantage: Abbott operates across four primary segments—medical devices, diagnostics, nutrition, and pharmaceuticals—achieving nearly $44.3 billion in revenue for FY 2025, reflecting a 5.7% year-over-year growth that underscores its stable cash flows and broad customer base across market cycles.
- Intuitive Surgical's Growth Potential: Intuitive Surgical reported approximately $10.1 billion in revenue for FY 2025, marking a significant 20.5% increase, with its robotic surgery platform installed in over 7,500 hospitals globally, indicating strong market demand and high profit margins.
- Financial Health Comparison: Abbott's debt-to-equity ratio stands at about 0.3, indicating a relatively stable financial position, while Intuitive Surgical boasts virtually no debt with a 0.0 ratio and a current ratio of 4.9, showcasing excellent liquidity.
- Risks and Regulatory Challenges: Abbott faces product liability and legal risks, particularly related to its infant formula, while Intuitive Surgical must navigate complex global regulations and cybersecurity threats, factors that could impact the future market performance of both companies.
See More
Long-Term Investment Strategy in Healthcare Sector
- Strong Financial Performance: Johnson & Johnson reported Q1 revenue of $24.1 billion, a 9.9% increase year-over-year, with adjusted EPS of $2.70 exceeding analyst expectations, and it forecasts annual sales between $99.7 billion and $100.7 billion, indicating robust growth potential in innovative medicine and medtech.
- Diversification Advantage: Abbott Laboratories achieved Q1 sales of $11.2 billion, up 7.8% year-over-year, with strong performance in medical devices and diagnostics offsetting declines in nutrition, and it expects full-year revenue growth of 6.5% to 7.5%, solidifying its position in global healthcare demand.
- Market Dominance: UnitedHealth Group's Q1 revenue reached $111.7 billion, a 2% increase year-over-year, with its Optum division leveraging data analytics and pharmacy care for vertical integration, projecting full-year EPS exceeding $17.35, up at least 31%, reinforcing its leadership in the U.S. private health insurance market.
- Stable Dividend Returns: Johnson & Johnson, Abbott, and UnitedHealth Group are all Dividend Kings, having increased dividends for 64, 54, and 17 consecutive years respectively, showcasing their strong cash flow management and appeal to long-term investors, particularly in times of economic uncertainty, providing low volatility and high margin of safety.
See More
Omnipod 5 Insulin Delivery System Launches in Spain
- Global Expansion: Insulet Corporation has launched the Omnipod 5 Automated Insulin Delivery System in Spain, marking the 26th country for sales and accelerating the company's international growth in diabetes management, which is expected to significantly enhance market share.
- Market Demand: With over 4.6 million adults living with diabetes in Spain, including approximately 189,000 individuals (and over 18,500 children and adolescents aged 0-19) relying on insulin for type 1 diabetes, the introduction of Omnipod 5 will provide these patients with more convenient management tools, improving their quality of life.
- Technological Innovation: The Omnipod 5 system automatically adjusts insulin every five minutes to improve glycemic control and reduce HbA1c levels without the need for multiple daily injections, which is expected to greatly enhance patient adherence and satisfaction with their treatment.
- Data Platform: The newly launched Omnipod Discover data management platform offers clear diabetes data analytics for users and healthcare providers, supporting personalized care and is anticipated to strengthen interactions between patients and their healthcare teams, improving treatment outcomes.
See More
AbbVie Q1 Earnings Beat Expectations, Market Reacts Positively
- AbbVie Revenue Growth: AbbVie reported Q1 revenues of $15 billion, reflecting a year-on-year increase of 12.4% and exceeding analyst expectations by 1.7%, showcasing strong performance from key growth drivers and enhancing the full-year outlook.
- Moderna's Stellar Performance: Moderna achieved Q1 revenues of $389 million, soaring 260% year-on-year and surpassing analyst expectations by 55.8%, marking it as the fastest-growing company among peers, with its stock rising 75.2% since the report, indicating market optimism about its future.
- United Therapeutics Disappoints: United Therapeutics reported revenues of $781.5 million, down 1.6% year-on-year and falling short of analyst expectations, leading to a 3% decline in stock price, highlighting challenges faced in a competitive market.
- Halozyme Exceeds Expectations: Halozyme Therapeutics reported Q1 revenues of $376.7 million, up 42.2% year-on-year and beating analyst expectations by 6.1%, despite a slight miss on full-year EPS guidance, with stock up 16.5%, reflecting market recognition of its technology.
See More
Schwab U.S. Dividend ETF Shows Strong Performance
- CAGR Performance: The Schwab U.S. Dividend ETF has achieved a compound annual growth rate (CAGR) of 13.3% since its inception in 2011, indicating strong performance despite not being available for a full 15 years.
- Dividend Contribution: Approximately 38% of the ETF's total returns come from dividends, highlighting their significance in investment returns; without dividends, an initial $10,000 investment would only be worth about $38,000 today.
- Portfolio Diversity: The ETF currently holds 103 stocks, primarily investing in financially sound U.S. companies that consistently pay dividends, such as Merck, Home Depot, and Coca-Cola, ensuring stability and profitability in its investments.
- Market Comparison: While the Schwab ETF has performed well, an investment of $10,000 in the S&P 500 index fund on October 20, 2011, would have grown to approximately $79,700, illustrating the competitive nature of the market.
See More
The Potential and Returns of Dividend Investing
- Significant Investment Returns: An investment of $10,000 in the Schwab U.S. Dividend Equity ETF 15 years ago would be worth approximately $61,200 today, showcasing the fund's strong performance and appeal.
- Compound Annual Growth Rate: The ETF has achieved a compound annual growth rate of 13.3% since its inception, with an impressive 29% growth rate over the past 12 months, indicating its competitive edge and investment value in the market.
- Importance of Dividends: Dividends accounted for about 38% of total returns since 2011; without them, a $10,000 investment would only be worth $38,000, highlighting the critical role dividends play in investment returns.
- Comparison with S&P 500: While the Schwab ETF has performed well, it still lags behind the Vanguard 500 Index Fund, which would have turned a $10,000 investment into approximately $79,700 during the same period, illustrating the diversity of market options and the importance of selection.
See More
Investment Comparison: Abbott vs. Intuitive Surgical
- Abbott's Diversification Advantage: Abbott operates across four primary segments—medical devices, diagnostics, nutrition, and pharmaceuticals—achieving nearly $44.3 billion in revenue for FY 2025, reflecting a 5.7% year-over-year growth that underscores its stable cash flows and broad customer base across market cycles.
- Intuitive Surgical's Growth Potential: Intuitive Surgical reported approximately $10.1 billion in revenue for FY 2025, marking a significant 20.5% increase, with its robotic surgery platform installed in over 7,500 hospitals globally, indicating strong market demand and high profit margins.
- Financial Health Comparison: Abbott's debt-to-equity ratio stands at about 0.3, indicating a relatively stable financial position, while Intuitive Surgical boasts virtually no debt with a 0.0 ratio and a current ratio of 4.9, showcasing excellent liquidity.
- Risks and Regulatory Challenges: Abbott faces product liability and legal risks, particularly related to its infant formula, while Intuitive Surgical must navigate complex global regulations and cybersecurity threats, factors that could impact the future market performance of both companies.
See More
